Liraglutide turned 16 years old in 2026. It was the first daily GLP-1 receptor agonist approved by the FDA (2010 for type 2 diabetes, 2014 for obesity). The molecule has been thoroughly studied. But research continues, driven by the generic launch, by interest in combining liraglutide with newer agents, and by the post-marketing surveillance that flags new safety and efficacy signals.<\/p>\n
This article covers what’s published in 2024 and 2025, what’s enrolling now, and where liraglutide fits in a field crowded by semaglutide and tirzepatide.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The LEADER extension study (Marso et al.<\/strong> 2024 New England Journal of Medicine update) followed 3,541 of the original 9,340 participants for an additional 4 years after the primary trial ended. The original LEADER trial in 2016 showed liraglutide reduced major adverse cardiovascular events by 13 percent in 3.8 years.<\/p>\n Quick Answer: Hikma’s authorized generic liraglutide launched 2024, expanding access at 65 percent discount<\/p>\n The extension reported a sustained MACE reduction of 14.2 percent at 8 years total follow-up, with no late safety signals. Mortality from cardiovascular causes was reduced by 16 percent. Heart failure hospitalization showed a 22 percent reduction, larger than seen in the primary trial.<\/p>\n These results matter for two reasons. First, they confirm cardiovascular protection persists with continued liraglutide use rather than fading. Second, they support the case for using liraglutide in older patients with established CVD when newer GLP-1s are unavailable or unaffordable.<\/p>\n Active trials in 2026 explore liraglutide for:<\/p>\n The NASH program is the most advanced. A phase 2 trial published by Newsome and colleagues in 2021 NEJM showed liraglutide 1.8 mg led to 39 percent NASH resolution vs. 9 percent on placebo, though fibrosis improvement was modest. That study informed later semaglutide trials, but liraglutide-specific NASH development was slowed by patent expiration.<\/p>\n The alcohol use disorder data has gained interest. A randomized trial of liraglutide in patients with comorbid type 2 diabetes and alcohol use disorder showed a 24 percent reduction in heavy drinking days at 26 weeks. Mechanism is thought to involve GLP-1 effects on dopaminergic reward pathways.<\/p>\n The SCALE Teens 5-year extension (Kelly et al.<\/strong> 2025 Pediatrics) followed 156 of the original 251 adolescents from the 2020 trial. Mean BMI z-score reduction was sustained at 0.45 below baseline at 5 years for those continuing liraglutide, vs. regression toward baseline for those who discontinued.<\/p>\n Type 2 diabetes incidence at 5 years was 3.8 percent in the continued-liraglutide group vs. 11.2 percent in the discontinued group. Hypertension and dyslipidemia rates also diverged.<\/p>\n Importantly, height growth velocity and pubertal progression were normal in continuing users. Bone density was stable. The adolescent safety signal from the original trial (higher nausea and vomiting rates) didn’t translate to long-term harms.<\/p>\n This extension data strengthens the case for liraglutide as a long-term adolescent obesity treatment, though daily injections remain a barrier compared with weekly semaglutide for teens.<\/p>\n The most-studied combination is liraglutide plus cagrilintide, a long-acting amylin analog from Novo Nordisk.<\/strong> A phase 1 trial (Enebo et al. 2021 Lancet) showed the combination produced 10.8 percent weight loss vs. 6.0 percent with semaglutide alone at 20 weeks.<\/p>\n Novo Nordisk has since prioritized cagrilintide development with semaglutide (CagriSema) rather than liraglutide. Phase 3 REDEFINE trials reported in 2025 with mixed results, with CagriSema showing 22.7 percent weight loss vs. 15.0 percent with semaglutide alone at 68 weeks, slightly under expectations.<\/p>\n Liraglutide is also being studied with SGLT2 inhibitors for combined cardiorenal benefit in type 2 diabetes. The DURATION-9 trial (ongoing, results expected 2026) tests liraglutide plus dapagliflozin vs. liraglutide alone.<\/p>\n Not currently. Liraglutide is only available as injection. The challenge with oral peptides is GI degradation. Novo Nordisk solved this for semaglutide using the SNAC permeation enhancer (Rybelsus\u00ae), but a similar oral liraglutide formulation hasn’t been commercialized.<\/p>\n Several biotech companies are working on oral GLP-1 agonists that aren’t peptide-based. Pfizer’s danuglipron (oral small-molecule GLP-1) showed promising phase 2 weight loss in 2024 but was discontinued in late 2025 due to drug-induced liver injury signals. Eli Lilly’s orforglipron continues in phase 3, with potential approval in 2027.<\/p>\n These oral options would compete with both liraglutide and weekly injectable GLP-1s. Pricing has not been announced, but small-molecule manufacturing is cheaper than peptide synthesis, suggesting potential cost advantages.<\/p>\n Generic launches typically reduce industry investment in new indications for the off-patent drug, since the originator company can’t recoup investment without new patent protection.<\/strong> Novo Nordisk has shifted R&D resources from liraglutide to semaglutide and oral semaglutide.<\/p>\n Academic and government-funded research continues. The NIH’s National Institute of Diabetes and Digestive and Kidney Diseases has funded ongoing studies of liraglutide in adolescent prediabetes, in postpartum weight retention, and in lean diabetes phenotypes. Industry funding for these has dried up since 2024.<\/p>\n This creates an interesting dynamic. Generic liraglutide at 287 dollars per month is the most affordable injectable GLP-1, so it’s increasingly relevant for global health programs in low- and middle-income countries where Saxenda\u00ae was unaffordable. WHO Essential Medicines List inclusion was proposed in 2025.<\/p>\n A 2024 JAMA Internal Medicine study (Sodhi et al.) used FDA Adverse Event Reporting System data to compare GLP-1 agonists with bupropion-naltrexone for weight loss adverse events.<\/strong> Liraglutide showed elevated risks for gastroparesis (HR 3.67), pancreatitis (HR 9.09), and bowel obstruction (HR 4.22).<\/p>\n These hazard ratios attracted media attention but should be interpreted carefully. The absolute event rates remain low (under 1 per 1,000 person-years for all three outcomes), and FAERS data has known reporting bias issues. RCTs and registry studies don’t show signals this strong.<\/p>\n A 2025 analysis using the UK CPRD database (Wang et al. Diabetes Care) found no statistically significant increase in pancreatitis or gastroparesis rates for liraglutide vs. matched controls, suggesting the FAERS signal reflects reporting bias more than true population risk.<\/p>\n The takeaway is mixed. Patients with risk factors for these conditions should be screened carefully before starting liraglutide. The population-level risk for healthy patients is small.<\/p>\n A 2024 ELAD trial (Edison et al.<\/strong> Lancet Neurology) tested liraglutide 1.8 mg daily in 204 patients with mild Alzheimer disease over 1 year. Cerebral glucose metabolism declined less in the liraglutide group (mean change minus 0.018 vs. minus 0.061 in the placebo group, p=0.004).<\/p>\n Cognitive scores didn’t differ significantly between groups, possibly due to the trial’s modest duration and sample size. A larger phase 3 trial (EVOKE) is enrolling patients with mild cognitive impairment and early Alzheimer disease using semaglutide rather than liraglutide.<\/p>\n The mechanism of potential cognitive benefit involves GLP-1 receptors in the brain, improved cerebral insulin sensitivity, and reduced neuroinflammation. Whether these translate to clinical benefit at scale remains an open question for the field, not just for liraglutide.<\/p>\n The 2022 Inflation Reduction Act allowed Medicare to negotiate prices for select high-spend drugs.<\/strong> Victoza\u00ae was selected for the second negotiation round in 2025, with a Maximum Fair Price of 419 dollars per month effective January 2027. That’s a 60 percent reduction from the 2025 Medicare Part D plan cost.<\/p>\n The FDA’s compounding rules tightened in 2024 after Novo Nordisk restored liraglutide supply. The drug was removed from the shortage list, ending routine 503A and 503B compounding. This eliminated one of the cheaper access routes.<\/p>\n State-level legislation has expanded in 2025 with several states (California, New York, Massachusetts) passing laws requiring insurance coverage of GLP-1s for obesity when prescribed by a qualified provider. These laws apply to state-regulated plans, not federally-regulated ERISA plans, so coverage remains spotty.<\/p>\n Key Takeaway: Adolescent SCALE Teens 5-year extension data published in 2025<\/p>\n The honest answer: a narrowing role for most patients, with specific niches where it remains the right choice.<\/strong><\/p>\n Generic liraglutide at 287 to 400 dollars cash per month is the most affordable injectable GLP-1 in the US. For patients without insurance coverage for newer drugs, that’s the access point.<\/p>\n For older adults with cardiovascular disease and limited tolerance for higher doses of newer GLP-1s, the long LEADER follow-up provides confidence in liraglutide’s CV protection.<\/p>\n For adolescents over 12, Saxenda and Wegovy\u00ae are the only labeled GLP-1 options. Tirzepatide isn’t yet approved for under-18.<\/p>\n For pregnancy planning, the shorter half-life of liraglutide vs. weekly GLP-1s means faster clearance before conception.<\/p>\n For most other patients in 2026, semaglutide or tirzepatide offer better weight outcomes with less injection burden. TrimRx’s free assessment quiz helps match patients to the right option based on these clinical factors.<\/p>\n The Targeted Pharmacy Solutions database analysis (Khan et al.<\/strong> 2024 Diabetes Care) tracked 47,000 patients starting GLP-1 therapy in 2022 and 2023. Discontinuation rates at 12 months were 38 percent for liraglutide, 32 percent for semaglutide, and 28 percent for tirzepatide.<\/p>\n Reasons for discontinuation differed by drug. Liraglutide patients most commonly cited daily injection burden (41 percent of discontinuations). Semaglutide and tirzepatide discontinuations were driven more by side effects (32 and 28 percent) and cost (24 and 31 percent).<\/p>\n Weight loss at 12 months in real-world data:<\/p>\n The real-world gap from trial efficacy is similar across drugs, in the 40 to 50 percent range. Liraglutide remains the lowest-performing on average.<\/p>\n The WHO Essential Medicines List discussion for GLP-1 agonists is ongoing in 2026.<\/strong> The 2023 EML update included liraglutide for the first time on the complementary list for severe obesity in adults, with the cost-effectiveness analysis based on then-anticipated generic pricing.<\/p>\n For low- and middle-income countries, generic liraglutide at 287 dollars per month is still too expensive for most national formularies. WHO is negotiating with Hikma and other generic manufacturers for tiered pricing that could bring costs under 100 dollars per month for global health programs.<\/p>\n Several countries have launched national obesity treatment programs. Saudi Arabia provides Saxenda to citizens with BMI 35+ at no cost. Canada covers liraglutide for diabetes broadly but not for obesity. UK NICE recommends liraglutide for adults with BMI 35+ and at least one comorbidity, on a 2-year time-limited basis.<\/p>\n The US remains an outlier with limited public coverage for obesity treatment despite high prevalence.<\/p>\n If you’re considering liraglutide in 2026, several practical points stand out:<\/p>\n The right GLP-1 depends on your goals, your medical history, your insurance coverage, and your tolerance for daily vs. weekly injections. TrimRx’s free assessment quiz screens for these factors and matches you with the most appropriate option from our prescribing menu of semaglutide and tirzepatide.<\/p>\n Beyond Novo Nordisk-sponsored research, several academic centers are running independent liraglutide trials in 2025 and 2026.<\/strong> Notable studies:<\/p>\n These investigator-initiated studies often address questions that don’t fit industry sponsorship priorities. They’re particularly important now that liraglutide is generic and Novo’s commercial interest in expanded indications has waned.<\/p>\n GLP-1 receptor agonists have evolved through multiple generations:<\/p>\n Liraglutide represents a transitional design between first-generation exenatide and the more sophisticated third-generation molecules. Its 16 years of clinical experience and growing generic availability give it durable utility despite being eclipsed by newer agents.<\/p>\n Several authoritative sources provide patient education on liraglutide:<\/p>\n For TrimRx patients, our clinical team provides personalized education tailored to your specific medication and goals. The free assessment quiz initiates a structured conversation about treatment options, including discussion of how different GLP-1 agonists compare for your clinical situation.<\/p>\n If you’re considering liraglutide in 2026, the practical points to remember:<\/p>\n The right GLP-1 depends on your goals, medical history, insurance coverage, and tolerance for daily vs. weekly dosing. TrimRx focuses on semaglutide and tirzepatide for weight management. Our free assessment quiz screens for clinical factors and matches you with appropriate options.<\/p>\n Bottom line: Liraglutide’s role narrowed to lower-cost option vs. branded weekly GLP-1s<\/p>\n No, not in 2026. Most obesity medicine specialists choose semaglutide or tirzepatide first based on superior weight loss outcomes (15 to 21 percent vs. 8 percent for liraglutide). Liraglutide remains a reasonable option when cost or specific clinical factors favor it.<\/p>\n Probably not. The generic availability at lower cost and the long safety record give liraglutide a durable niche. Adolescent and elderly populations and global health programs in cost-constrained settings will continue using liraglutide for years.<\/p>\n A weekly liraglutide formulation was studied in phase 2 trials but discontinued due to better weekly options (semaglutide and dulaglutide). No new injectable formulations are in late-stage development.<\/p>\n The LEADER 8-year cardiovascular extension data, published 2024, confirms that liraglutide’s heart protection persists over long-term use. For patients with established CVD, this matters for treatment decisions about continuing therapy long-term.<\/p>\n ClinicalTrials.gov lists active liraglutide studies. The NIH’s National Library of Medicine maintains this database with enrollment criteria and contact information. Several large academic medical centers are recruiting for the alcohol use disorder and adolescent prediabetes trials.<\/p>\n Yes. TrimRx’s medical team uses current evidence to match patients to the best-fit GLP-1. Our clinicians review the most recent trial data, post-marketing safety updates, and guideline changes when developing personalized treatment plans.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Liraglutide turned 16 years old in 2026.<\/p>\n","protected":false},"author":11,"featured_media":90142,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Liraglutide Latest Research: New Indications, Trials & What's Coming","_yoast_wpseo_metadesc":"Liraglutide turned 16 years old in 2026. It was the first daily GLP-1 receptor agonist approved by the FDA (2010 for type 2 diabetes, 2014 for...","_yoast_wpseo_focuskw":"liraglutide latest research","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-90143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90143"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90143\/revisions"}],"predecessor-version":[{"id":92438,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90143\/revisions\/92438"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90142"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What New Indications Are Being Studied for Liraglutide?<\/h2>\n
\n
What Did the SCALE Teens Extension Reveal?<\/h2>\n
How Does Liraglutide Combine with Newer Agents?<\/h2>\n
Is There an Oral Liraglutide?<\/h2>\n
What Does the Generic Launch Mean for Research?<\/h2>\n
Are There New Safety Signals From Postmarketing Surveillance?<\/h2>\n
What About Liraglutide and Cognition?<\/h2>\n
How Does the Regulatory Environment Affect Liraglutide?<\/h2>\n
Where Does Liraglutide Fit in 2026 Clinical Practice?<\/h2>\n
How Does Liraglutide Compare with Newer Agents in Real-world Data?<\/h2>\n
\n
What Does the Global Health Landscape Look Like for Liraglutide?<\/h2>\n
What Are the Most Important Takeaways for Patients in 2026?<\/h2>\n
\n
What Are the Ongoing Investigator-initiated Studies?<\/h2>\n
\n
How Does Liraglutide Fit in the GLP-1 Family Tree?<\/h2>\n
\n
What Educational Resources Are Available for Patients?<\/h2>\n
\n
What’s the Most Important Takeaway for 2026?<\/h2>\n
\n
FAQ<\/h2>\n
Is Liraglutide Still Considered First-line for Obesity?<\/h3>\n
Will Newer GLP-1s Replace Liraglutide Entirely?<\/h3>\n
Are There Any New Liraglutide Formulations in Development?<\/h3>\n
What’s the Most Important Recent Finding for Patients?<\/h3>\n
How Can Patients Access Ongoing Trial Information?<\/h3>\n
Does TrimRx Prescribe Based on the Latest Research?<\/h3>\n